The board wants a single number for regulatory risk exposure. Your quality team gives you a spreadsheet with 200 rows and no summary. You're staring at disparate data points, trying to distill it into
Here's what's happening right now: As of March 29, 2026, there are 26,202 new regulatory signals in the market. This includes 26,000 new FDA Adverse Event Reports (MAUDE/MDRs) and 202 new Health Canada mdl entries. These numbers represent the raw volume of post-market activity you need to contextualize for risk assessment and compliance reporting.
For a VP Quality/Regulatory, this data isn't just noise—it's critical for quantifying risk exposure and informing your board. The surge in adverse events signals potential systemic issues that could impact your product portfolio or competitive landscape. In management review, you must translate these signals into trends, such as whether specific device categories are driving the increase, to align with QMSR and 21 CFR 820 requirements for proactive quality oversight.
We analyzed this across 548,000+ regulatory records and found that aggregating signals into product-specific risk scores can streamline reporting and highlight areas needing immediate attention. This approach moves beyond spreadsheets to provide the concise metrics your stakeholders demand.
See how your specific product codes compare and access tools for risk quantification at truemeddevice.com.
Related Regulatory Signals
[SHIRAKAWA OLYMPUS CO., LTD.] VISERA VIDEO SYSTEM CENTER — Malfunction
[TANDEM DIABETES CARE] T:SLIM X2 INSULIN PUMP WITH CONTROL-IQ TECHNOLOGY — Malfunction
[AESCULAP INC.] AESCULAP — Malfunction
BUR, ROUND
CEDARS-SINAI CARDIAC SUITE
SELF-CATH CLOSED SYSTEM PRE-LUBRICATED URINARY INTERMITTENT DRAINAGE CATHETER
See how these signals relate to your device
Start a free pilot to match signals to your product portfolio automatically.
Start PilotRelated Articles
Management review is next week. ISO 13485 5.6 requires external signal data as input. Your team hasn't gathered it yet, and you're staring at a blank slide for the board report on risk exposure and co
Here's what's happening right now: There were 10,384 new regulatory signals today, including 10,360 FDA Adverse Event Reports (MAUDE/MDRs) and 22 Health Canada mdl entries. Notably, Health Canada issued 2 new recalls: Auro-Canagliflozin for incorrect DIN labeling and LUXA-D for a foreign product in a capsule, both flagged for product safety. For your management review under QMSR and 21 CFR 820, this data isn't just noise—it's critical for quantifying risk exposure and benchmarking against compe
April 4, 2026
social_linkedinComplaint trends are rising for one product family but you can't tell if it's an industry-wide issue or yours alone. You're reviewing your CAPA dashboard, trying to prioritize investigations against l
Here's what's happening right now: 10,384 new regulatory signals hit the system today. That includes 10,360 new FDA adverse event reports (MAUDE/MDRs) and 2 new Health Canada recalls. One recall involves incorrect DIN labeling on a blister card (Auro-Canagliflozin), and another involves a foreign product in a capsule batch (LUXA-D). For your CAPA prioritization and complaint handling, notice the pattern in the MDRs: multiple reports for infusion set tubing detachment events and software/app mal
April 4, 2026
social_linkedinA competitor's device just got recalled. Your auditor will ask: 'How did you evaluate whether this affects your products?' You're reviewing the alert, knowing it could trigger a supplier audit or requ
Here's what's happening right now: 2 new Health Canada recalls were issued this week, both for product safety issues. Auro-Canagliflozin has affected lots with incorrect DIN labeling on blister cards, and LUXA-D has a capsule containing a foreign product in the batch. This adds to 10,360 new FDA Adverse Event Reports (MAUDE/MDRs) and 22 new Health Canada mdl signals today, totaling 10,384 new regulatory signals. For RA Managers focused on audit preparedness and post-market surveillance, these s
April 4, 2026